Favorable short-term radiographic outcomes seen after TKA performed with posterior-stabilized implant
Click Here to Manage Email Alerts
Results from this study indicate patients who underwent total knee arthroplasty with a posterior-stabilized knee prosthesis designed by a single manufacturer had good short-term radiographic outcomes using the Knee Society Roentgenographic Evaluation Scoring System. However, investigators noted long-term survivorship analysis is needed.
“There was no significant change in alignment after at least 2 years of follow-up in 37 patients included in the study. We know from the currently available literature that implants that do not exhibit signs of loosening at this follow-up period will most likely stay stable for a long duration,” Khaled J. Saleh, MD, MSc, FRCSC, MHCM, CPE, told Healio.com/Orthopedics. “Definitely these are positive outcomes; however, we still need long-term observational studies and comparative studies, with up to 10 [years] to 15 years of follow-up, to establish the performance of the Vega system [Aesculap] in comparison to other available knee implants.”
Khaled J. Saleh
Saleh and colleagues followed 37 patients who underwent total knee arthroplasty (TKA) with the Vega System knee prosthesis using an anteromedial parapatellar approach. Patients were followed or a minimum of 2 years. Investigators assessed patients’ radiographs after 2 years postoperatively with the Knee Society Roentgenographic Evaluation Scoring System (KSRESS). The average radiographic follow-up was 36 months.
Results showed none of the patients required revision TKA. During the follow-up period, investigators noted stable femoral and tibial interface with no significant change in prosthesis alignment as evidenced by comparison of the first and last postoperative radiographs. Assessment with the KSRESS also showed no significant change in alignment. ‒ by Monica Jaramillo
Disclosure: Saleh reports he is a paid consultant for Aesculap/B. Brawn, Iroko Pharmaceuticals LLC and Watermark Inc-DSMB; and receives royalties from Aesuculap/B. Brawn.